Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised SEB in connection with an issue of additional Tier 1 captial of MUSD 600
Mandate

Vinge has advised SEB in connection with an issue of additional Tier 1 captial of MUSD 600

March 27, 2017 Capital Markets and Public M&A

Vinge has advised Skandinaviska Enskilda Banken AB (publ) (“SEB”) as to Swedish law in connection with the bank’s issue of Additional Tier 1 Capital in the amount of MUSD 600 in the form of a debt instrument with no final maturity and with automatically conversion into Class A-shares if the CET1 ratio of the bank decreases to a certain level.

The instrument is listed on the Global Exchange Market regulated by the Irish Stock Exchange.

SEB issued the Additional Tier 1 Capital to refinance an old similar instrument that reaches its call date later this year and to optimize its capital structure.

Vinge’s team consisted mainly of Göran Nyström, Charlotte Levin, Albert Wållgren and Malte Hedlund.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026